Developing new treatments for hard-to-target RAS-related cancers
Targeting undruggable RAS for cancer treatment
['FUNDING_OTHER'] · UNIV OF NORTH CAROLINA CHAPEL HILL · NIH-10898867
This study is looking for new ways to help treat pancreatic cancer by targeting a protein called RAS, which is often involved in this type of cancer, and it aims to find better treatments for patients dealing with RAS-related cancers.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIV OF NORTH CAROLINA CHAPEL HILL (nih funded) |
| Locations | 1 site (CHAPEL HILL, UNITED STATES) |
| Trial ID | NIH-10898867 on ClinicalTrials.gov |
What this research studies
This research focuses on making the RAS protein, which is often involved in cancer, easier to target with treatments. The principal investigator has over 30 years of experience in RAS research and aims to develop therapies specifically for pancreatic ductal adenocarcinoma, a type of cancer with a high mutation rate in the KRAS gene. The approach includes exploring novel strategies to degrade MYC, another protein that works closely with RAS in promoting cancer growth. By identifying new ways to interfere with these proteins, the research hopes to create effective treatments for patients with RAS-driven cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma or other cancers associated with RAS mutations.
Not a fit: Patients with cancers not driven by RAS mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new, effective therapies for patients with pancreatic cancer and other RAS-related cancers.
How similar studies have performed: While targeting RAS has been challenging, there is growing interest and some early successes in developing therapies for RAS-driven cancers, making this research both innovative and timely.
Where this research is happening
CHAPEL HILL, UNITED STATES
- UNIV OF NORTH CAROLINA CHAPEL HILL — CHAPEL HILL, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DER, CHANNING J. — UNIV OF NORTH CAROLINA CHAPEL HILL
- Study coordinator: DER, CHANNING J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Cause, Cancer Etiology, Cancer Treatment, Cancers